myirislogo
26 May, 2015 21:08 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
State Bank O 277.25 0.16
Tata Motors 497.10 1.60
Bhel 241.00 2.88
I T C 314.30 1.05
Tata Stl 332.85 0.03
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Wockhardt Limited
Wockhardt Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532300NSE:WOCKPHARMABloomberg:WPL@INReuters:WCKH.BO
Market Lot: 1Face Value: 5ISIN Demat: INE049B01025
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
21-MAY-15 Wockhardt, one of the leading pharmaceutical and biotechnology company, announced today that that US Food and Drug Administration (FDA) has granted WCK 4873, a product from their New Drug Discovery program, Qualified Infectious Disease Product (QIDP) status. 28-APR-15 Wockhardt, one of the leading pharmaceutical and biotechnology company, announced that during the last US FDA cGMP inspection of the facilities at L1- Chikalthana and W...   More..
Business Profile Future Plans
CEO Talk
Wockhardt Ltd is exploring possibilities of co-licensing WCK-771 and WCK-919. The company intends to focus essentially on the anti-infective therapeutic segment as it accounts for 12 per cent of the total pharma market and is the third largest therapeutic segment.   Habil Khorakiwala
One To One
Recent news
Latest News
Wockhardt shares tumble on drug recall  -IRIS 28-Apr-15
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2014(9)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 13957.7018052.7024711.80
Other Income4399.502787.40653.40
Total Income18357.2020840.1025365.20
Cost of goods sold13665.4017392.6018998.20
OPBDIT4691.803447.506367.00
PAT3458.801986.106227.00
Gross Block---
Equity capital550.20548.80547.90
EPS (Rs.)-18.1056.88
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-18.60 - 114.3610.51 - 38.08
Debt / Equity (x)---
Operating margin (% of OI)25.616.525.1
Net margin (% of OI)18.8 9.524.5
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Wockhardt Towers
Bandra Kurla Complex
Bandra (East)
Mumbai
Maharashtra-400 051
PHONE
(022) 2653 4444
FAX
(022) 2653 4242
 
Board of Directors
Board Meetings
Date Purpose
28-MAY-15 A meeting of the Board of Directors of the Company will be held on May 28, 2015, inter alia, to consider the following items: 1. Approval of the Annual Audited Consolidated and Standalone Financial Statements of the Company for the year ended March 31, 2015 and Boards? Report along with other Annexures, 2. Approval of the Audited Consolidated and Standalone financial results of the Company for the fourth quarter and year ended March 31, 2015 and 3. Recommendation of dividend on Preference Shares, if any. Further, pursuant to Company?s code for prevention of insider trading the Trading window is closed from May 14, 2015 to May 30, 2015 (both days inclusive). The Trading Window shall re-open 48 hours after the financial results are submitted to the stock exchanges. & Audited Results
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer